Aim: The microtubule-associated Tau protein is a marker of paclitaxel sensitivity in ovarian cancer. The aim of the present study was to elucidate the function of the Tau protein in epithelial ovarian cancer.
| INTRODUCTION
Ovarian cancer (OC) is the leading cause of death among patients with gynecological cancer. Paclitaxel and platinum-based chemotherapy often are used as the first-line chemotherapy in the treatment of patients with epithelial OC. Almost all patients with epithelial OC are good responders to paclitaxel and platinum-based chemotherapy.
However, some patients experience a relapse and require secondline chemotherapy. A useful marker of a sensitivity to paclitaxel and platinum-based chemotherapy has not been previously identified.
It is well known that the Tau protein is related to Alzheimers disease. The accumulation of hyperphosphorylated and aggregated microtubule-associated protein Tau (MAPT) is a central feature of a class of neurodegenerative diseases that are termed "tauopathies." The continuing increase in the adult-born neurons indicates that tauopathies are characterized by increased neurogenesis. 1 The molecular weight of the Tau protein is 50-64 kDa and it is a product of the TAU gene that is located in chromosome 17. In addition to neurons, Tau is expressed at low levels in several non-neuronal cells. The Tau protein consists of a N-terminus and a C-terminus. It has a microtubule-binding part at the C-terminus. In the mammalian brain, the Tau protein has six isoforms that differ in the number of microtubule-binding domain repeats (three or four). 2 The Tau protein binds to beta-tubulin and thus stabilizes the microtubules. Paclitaxel exhibits its effect through the exact same mechanism. Therefore, the Tau protein and paclitaxel compete for binding to the microtubules.
Recently, the Tau protein has been identified as a marker of response to paclitaxel in breast cancer and OC. 3, 4 It was reported that the negative expression of the Tau protein appears to be both a good prognostic factor and a predictor of the response to paclitaxel and platinum-based chemotherapy in patients with epithelial OC. 4 Another study also reported that low Tau protein expression might be used as a marker to select patients for paclitaxel therapy. 5 In the field of gynecological oncology, very little work has been done on the Tau protein.
As described above, the Tau protein and paclitaxel bind to the same part of the microtubules, thereby promoting tubulin polymerization and microtubule stabilization. This is the mechanism of the antitumor action of paclitaxel. In the field of neurology, it is well known that phosphorylation of the Tau protein causes apoptosis of the neurons;
the Tau protein is closely related with cell apoptosis. Therefore, the authors researched the function of the Tau protein with respect to the effect of paclitaxel. The OC cell line was selected because paclitaxel and platinum-based chemotherapy are the first-line chemotherapy regimen for epithelial OC. However, the role of the Tau protein in cancer cells has not been clarified yet. Therefore, Tau protein function was analyzed in epithelial OC cells in this study.
| MATERIALS AND METHODS

| Cell lines and cell culture
The TOV112D, MCAS, and OVCAR3 cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). The TOV112D is derived from human endometrioid carcinoma, 6 MCAS is derived from human mucinous carcinoma, 7 and OVCAR-3 is derived from human serous carcinoma. 8 The OVICE cell line that is derived from human clear cell carcinoma was obtained from the Japanese
Collection of Research Bioresources Cell Bank (Osaka, Japan). 9 The HRA cells and DISS cells, derived from human epithelial ovarian carcinoma, were generously provided by the National Defense Medical
College, Tokorozawa, Japan, 10 and Jichi Medical School, Tochigi, Japan
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, respectively. All the cells were grown in Roswell Park
Memorial Institute (RPMI) medium-1640 (Sigma-Aldrich, St. Louis, MO, USA) and supplemented with 10% fetal bovine serum, at 37°C, in a water-saturated atmosphere with 5% CO 2 and 95% air. 12 All the cell lines were verified in writing as being ovarian in origin and no mycoplasma contamination was present. 
| Plasmid DNA preparation
A pCMV6-AC-GFP vector (OriGene Technologies, Inc., Rockville, MD, USA) was used that encodes the human MAPT transcript variant 1
and is fused to green fluorescent protein (GFP) and the ampicillin resistance gene. For amplification, pCMV6-AC-GFP was transformed into DH5α-competent cells via heat-shock transformation, according to the standard laboratory protocols. 13 The transformed bacteria were amplified in lysogeny broth-ampicillin medium. 13 The plasmids were purified from cultured, transformed bacteria by using a PureLink HiPure Plasmid Filter Maxiprep DNA purification kit (Invitrogen Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. 13 The plasmid DNA was diluted in sterile water at a concentration of 3 μg/μL.
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| Small interfering RNA preparation
The sequence of the small interfering RNA (siRNA) duplex that was specific for MAPT was synthesized commercially by OriGene
Technologies. The siRNA tube was briefly centrifuged in order to ensure that all the contents collected at the bottom of the tube and the duplexes were resuspended in the provided RNase-free duplex buffer.
The tube was heated to 94°C for 2 minutes and subsequently cooled to room temperature.
| In vitro plasmid DNA transfection
One day before transfection, 0.5×10 7 TOV112D and HRA cells were plated and cultured in 15 mL of RPMI medium-1640 that was supplemented with 10% fetal bovine serum without antibiotics in 10 cm culture dishes so that they would reach 80% confluence at transfection. 12 Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA, USA) was used for the DNA transfection. Next, 24 μg of MAPT DNA was diluted in 1000 μL of phosphate-buffered saline (PBS) and 60 μL of lipofectamine was diluted in 1000 μL of PBS.
Then, the dilutions were incubated for 5 minutes at room temperature. After the incubation, the DNA and lipofectamine were combined and incubated for 20 minutes at room temperature. After the incubation, 2000 μL of the complexes were added to each 10 cm culture dish. The vector without MAPT DNA was used as the control. The control cells were given only a mixture of the vector and lipofectamine.
| In vitro small interfering RNA transfection
One day before transfection, 0.2×10 7 TOV112D and OVCAR3 cells were plated and cultured in 15 mL of RPMI medium-1640 that was supplemented with 10% fetal bovine serum without antibiotics in 10 cm culture dishes so that they would reach 50% confluence at transfection. 12 Lipofectamine 3000 was used for the siRNA transfec- 
| Western blot analysis
Cell lysates were prepared from the TOV112D, OVCAR3, HRA, DISS, 
| Cell proliferation assay
The level of cell proliferation was assayed by using a cell-counting kit (CCK-8; Dojin Laboratories, Kumamoto, Japan). 12 The TOV112D
and HRA cells were cultured overnight in 96-well microplates at 4.0×10 4 cells per well with 100 μL of medium. Afterwards, a solution of lipofectamine and DNA complex that contained 0.1 μg of human MAPT DNA was added to the cells. The control group was given only a mixture of the vector and lipofectamine. The transfected cells were incubated at 37°C in a CO 2 incubator for 48 hours. 12 Afterwards, paclitaxel was added to the cells in four pattern concentrations-0, 1, 10, and 50 μg/mL-and incubated at 37°C in a CO 2 incubator for 48 hours. The level of cell proliferation was assessed 4 hours after the addition of the CCK-8 by measuring A 450 with a Multiskan FC microplate reader (Thermo scientific, Yokohama, Japan). 12 A preliminary study using this kit showed that the absorbance was directly proportional to the number of cells. 12 The experiment was conducted in triplicate. The proliferation of the TOV112D and OVCAR3 cells also were assessed by adding a solution of lipofectamine and siRNA complex that contained 5 pmol human MAPT siRNA.
| Cell cycle analysis
A cell cycle analysis was performed by using the Cell Cycle Phase Determination Kit (Cayman chemical, Ann Arbor, MI, USA). The TOV112D (control), MAPT DNA-transfected TOV112D, and MAPT siRNA-transfected TOV112D cells were collected and centrifuged to pellet them at the bottom. After centrifugation, the cells were washed twice with an assay buffer and the cell pellet was resuspended to a density of 10 6 cells/mL in the assay buffer. In order to fix and permeabilize the cells, 1 mL of fixative was added to each sample. Next, the fixed cells were centrifuged at 500 g for 5 minutes and the fixative was decanted.
The cell pellet was suspended in 0. 
| Apoptosis analysis
The apoptosis analysis was performed by using the Annexin V-FITC Then, 400 μL of the binding buffer was added and the cell samples were analyzed by flow cytometry.
| Statistical analysis
All the statistical analyses were performed by using the Student's t test and all the P-values that were <.05 were considered to be statistically significant.
| RESULTS
| Expression levels of the Tau protein in various cell lines
A Western blot analysis showed that the expression level of the Tau protein was the highest in the TOV112D cells (Fig. 1 (Fig. 2B) . In the TOV112D and HRA cells, transfection with MAPT DNA increased the expression of the Tau protein, whereas in the TOV112D and OVCAR3 cells, transfection with MAPT siRNA decreased the expression of the Tau protein ( Fig. 2A,B) . In particular, the transfection of MAPT DNA showed multiple bands and its phenomenon suggested hyperphosphorylation. 
| Alteration of apoptosis after microtubuleassociated protein Tau DNA or microtubule-associated protein Tau small interfering RNA transfection
Although the Annexin-V+/PI-cells showed early apoptosis, the Annexin-V+/PI+ cells showed late apoptosis. In the control cells, the average rate of total apoptosis was 12.8% (average early apoptosis, 11.3%; late apoptosis, 1.5%). In the DNA-transfected cells, the aver- Fig. 6 ). DISS, and HRA are types of serous carcinoma. OVISE is a type of clear cell carcinoma. MCAS is a type of mucinous carcinoma. In a previous study, the primary tumors of 74 patients with OC were immunohistochemically stained for the Tau protein. 4 The number of Tau-positive patients was compared between the patients with the serous and those with the non-serous type. However, it was reported that there was no significant difference between the histological types. In this study, there was a difference in the Tau expression levels among patients with the same histological type. The HRA and OVCAR3 cells are types of serous carcinoma and there are many other histological types of OC cells. Accordingly, there is the need to research Tau protein level expression in other cell types. One study compared the level of Tau protein expression among five types of serous OC cells. 16 The level of Tau protein expression was different in each type. 16 The reason for the difference in Tau protein expression among the histological types or among individuals is unclear. 16 Other research reported that repeated sequences, CpG islands, and haplotypes affect the DNA and RNA levels of MAPT and regulate MAPT gene expression. 17 These factors might have different actions among the cells of each histological type.
| DISCUSSION
The Tau protein recently has been identified as a marker of response to paclitaxel in breast cancer. 5, [18] [19] [20] [21] [22] The Tau protein and paclitaxel compete to bind to the microtubules. Therefore, the sensitivity to paclitaxel should be weak in cells with a high Tau protein expression.
A study examined the Tau expression of 74 patients with epithelial OC and compared the progression-free survival (PFS) and 3 year overall survival (OS). 4 The PFS of the Tau-negative patients was significantly better than that of the Tau-positive patients (P=.0355). In the univariate analysis, the 3 year OS of the Tau-negative patients was significantly better than that of the Tau-positive patients (P=.0198). 4 However, in the multivariate analysis, there was no significant difference. 4 It was concluded that negative Tau protein expression seems to be both a good prognostic factor and a predictor of the response to paclitaxel and platinum-based chemotherapy in patients with epithelial OC.
4
F I G U R E 6 Apoptosis analysis. The Annexin-V+/PI-cells show early apoptosis and the Annexin-V+/PI+ cells show late apoptosis. The average total (early + late) apoptosis rate of the control cells was 12.8% (average early apoptosis, 11.3%; average late apoptosis, 1.5%). The average total apoptosis rate of the DNA-transfected cells was 72.8% (average early apoptosis, 52.6%; average late apoptosis, 19.7%). There was a significant increase in apoptosis of the DNA-transfected cells. *P<.0001, compared to the control. The average total apoptosis rate of the small interfering RNA (siRNA)-transfected cells was 29.9% (average early apoptosis, 27.6%; average late apoptosis, 2.3%). There was a significant increase in apoptosis of the siRNA-transfected-cells. **P<.001, compared to the control. FITC, fluorescein isothiocyanate Conversely, another study reported that Tau expression was not associated with PFS or OS in serous epithelial OC. 23 Furthermore, many other factors affect PFS and OS, including the histological type, stage, residual tumor size, and age. Chemosensitivity is also influenced by many factors. [24] [25] [26] [27] [28] In the patients with epithelial OC, a sensitivity to both paclitaxel and platinum affected their response to chemotherapy. Therefore, the current authors investigated the relationship be- 
